Human Intestinal Amino Acid Absorption and the Role of a Local RAS

Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04524494

Enrollment

Registered

2020-08-24

Start date

2010-01-27

Completion date

2011-05-31

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renin-Angiotensin Aldosterone System (RAS)

Keywords

Renin Angiotensin System, Angiotensin Converting Enzyme 2 (ACE2), Angiotensin II AT1 Receptor Blocker, ACE inhibitors, intestinal amino acid absorption

Brief summary

This study is to find out what role a local intestinal RAS (renin angiotensin system) plays in the context of amino acid absorption in the human intestinal tract and how this RAS and thus the amino acid absorption is influenced by the RAS-active drugs (angiotensin II AT1 receptor blockers (sartans) or ACE inhibitors).

Interventions

OTHERbiopsy of intestinal tissue

4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

OTHERblood draw

40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

OTHERurine collection

Midstream Urine collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Body Mass Index (BMI): 18-35 kg/m2 * cohort 1: therapy with an angiotensin II AT1 antagonist or ACE Inhibitor * cohort 2: no therapy with an angiotensin II AT1 antagonist or ACE Inhibitor * Carrying out a diagnostic gastroscopy, colonoscopy or a combined gastroscopy / colonoscopy * Existence of written consent after detailed information about the study

Exclusion criteria

* Severe pathological changes in the gastrointestinal tract (e.g. sprue, stomach ulcers, malignancies); (reflux esophagitis and gastritis are not

Design outcomes

Primary

Measure	Time frame	Description
messenger ribonucleic acid (mRNA) quantification in intestinal tissue biopsy	single time-point at baseline	mRNA quantification in intestinal tissue biopsy: mRNA content coding for regulatory RAS protein is measured relative to the mRNA content, which codes for the structural protein villin.
amino acid concentration in blood sample	single time-point at baseline	amino acid concentration in blood sample by High Performance Liquid Chromatography (HPLC)
amino acid concentration in urine sample	single time-point at baseline	amino acid concentration in urine sample by HPLC (High Performance Liquid Chromatography)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026